Neurofilament Light Chain (NfL) assay
A simple blood test delivering key insights into MS disease activity
Receive your quote directly from the manufacturer.
Introducing NfL, the groundbreaking blood test first to be CE marked* for predicting the risk of future MS disease activity. The NfL assay is offered on the Atellica IM, Atellica CI, and ADVIA Centaur XP/XPT systems and provides fast, reproducible, novel insights into MS (Multiple Sclerosis) disease activity; from a simple blood draw using serum and plasma.†
NfL is not available for sale in the United States and may not be commercially available in all countries. Future availability cannot be guaranteed and is dependent on local regulatory requirements.
Assay specifications:
Sample type: Serum and EDTA Plasma
Analytical measuring range: 3.0 – 300.0 pg/mL
Sample volume: 100 µL
System availability:
Atellica IM Analyzer: Deliver innovative results with high reproducibility, workflow efficiency, and reduced operator intervention.
Atellica CI Analyzer: Unrivaled versatility using the same technology, assays, workflow and user interface as the Atellica Solution.
ADVIA Centaur XP/XPT Systems: Integrate NfL results onto a comprehensive immunoassay platform.
*CE 0197
†The Atellica IM NfL assay, in conjunction with clinical, imaging, and laboratory findings, is intended to be used as an aid in identifying adult patients between 18–55 years of age with Relapsing Multiple Sclerosis (RMS), who are at a higher versus lower risk of MS disease activity, as defined by new or enlarging T2 (neT2) magnetic resonance imaging (MRI) lesions, within a 2 year period.
